e-learning
resources
Virtual 2020
Pre-Congress Content
Digital health interventions in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Self-administration of biologics for severe asthma – development of an app – a qualitative study
K. Hansen (Vejle, Denmark), L. Ulrich (Vejle, Denmark), C. Porsbjerg (Copenhagen, Denmark), A. Christiansen (Odense, Denmark), O. Hilberg (Vejle, Denmark)
Source:
Virtual Congress 2020 – Digital health interventions in respiratory medicine
Session:
Digital health interventions in respiratory medicine
Session type:
E-poster session
Number:
1354
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Hansen (Vejle, Denmark), L. Ulrich (Vejle, Denmark), C. Porsbjerg (Copenhagen, Denmark), A. Christiansen (Odense, Denmark), O. Hilberg (Vejle, Denmark). Self-administration of biologics for severe asthma – development of an app – a qualitative study. 1354
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Patients' experiences of asthma exacerbation and management: a qualitative study of severe asthma
Source: ERJ Open Res, 7 (2) 00528-2020; 10.1183/23120541.00528-2020
Year: 2021
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study
Source: Annual Congress 2009 - Epidemiology of asthma
Year: 2009
Combination asthma medication and healthcare use in severe or difficult-to-treat asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Methodological issues in therapeutic trials of COPD
Source: Eur Respir J 2008; 31: 927-933
Year: 2008
The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study
Source: International Congress 2016 – Kaleidoscope of respiratory nursing
Year: 2016
Evaluating the effects of asthma therapy on childhood growth: principles of study design
Source: Eur Respir J 2002; 19: 1167-1178
Year: 2002
The clinical use of an internet-based asthma teleconsultation system
Source: Annual Congress 2006 - New developments in the management of asthma
Year: 2006
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
The development of an algorithm for the rational use of intravenous salbutamol in severe paediatric asthma
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008
Biologic therapies in paediatric severe asthma
Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma
Year: 2020
Challenges in classification of asthma severity from prescription data: a pilot study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
The use of omalizumab in the management of severe chronic paediatric asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting
Source: International Congress 2017 – Asthma management
Year: 2017
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept